*December 2022*
In non–small cell lung cancer, EGFR mutations, MET exon 14 skipping mutations, and HER2 mutations are common mutations for which directed therapies are available. New approaches and novel agents are constantly being developed to identify and treat emerging targets in non– small cell lung cancer (NSCLC). This article covers treatment updates on EGFR Exon 20, MET exon 14 skipping, and HER2 mutations. Read more.
